medicina58巻1号

2021年01月発行

特集 エキスパートに学ぶ—最新の循環器治療薬の使い方 知っておくべき10種類の循環器治療薬と治療法

—心不全に対する新規治療薬・1—アンジオテンシン受容体ネプリライシン阻害薬（ARNI）：エンレスト^®

著者： 稗田道成¹²

所属機関： ¹九州大学医学部第一内科心血管内科 ²九州大学医学大学院加齢病態修復内科学講座

ページ範囲：P.16 - P.23

Question 1
ARNIってどのような薬ですか？

参考文献

1）Kostis JB, et al：Omapatrilat and enalapril in patients with hypertension；The Omapatrilat Cardiovascular Treatment vs. Enalapril（OCTAVE）trial. Am J Hypertens 17：103-111, 2004

2）McMurray JJ, et al：Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371：993-1004, 2014

3）Velazquez EJ, et al：Angiotensin-neprilysin Inhibition in acute decompensated heart failure. N Engl J Med 380：539-548, 2019

4）Tsutsui H, M et al：Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction-Baseline characteristics and treatment of PARALLEL-HF Trial. Circ J 82：2575-2583, 2018

5）Tsutsui H, et al：Efficacy and safety of sacubitril/valsartan（LCZ696）in Japanese patients with chronic heart failure and reduced ejection fraction；Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol 70：225-231, 2017

6）Solomon SD, et al：The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction；A phase 2 double-blind randomised controlled trial. Lancet 380：1387-1395, 2012

7）Solomon SD, et al：Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381：1609-1620, 2019

8）Solomon SD, et al：Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141：352-361, 2020

9）McMurray JJV, et al：Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction. Circulation 141：338-351, 2020

10）Cunningham JW, et al：Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol 76：503-514, 2020

11）Ponikowski P, et al, Group ESD：2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure；The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology（ESC）developed with the special contribution of the Heart Failure Association（HFA）of the ESC. Eur Heart J 37：2129-2200, 2016

12）Yancy CW, et al：2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure；An update of the 2013 ACCF/AHA Guideline for the management of heart failure；A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134：e282-e293, 2016

13）Cannon JA, et al：Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Euro J Heart Fail 19：129-137, 2017

14）Langenickel TH, et al：The effect of LCZ696（sacubitril/valsartan）on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81：878-890, 2016